{"id":"NCT04024072","sponsor":"Padagis LLC","briefTitle":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","officialTitle":"Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Ophthalmic Suspension 1% to AzoptÂ® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-24","primaryCompletion":"2020-02-26","completion":"2020-04-30","firstPosted":"2019-07-18","resultsPosted":"2023-03-06","lastUpdate":"2023-03-06"},"enrollment":495,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Brinzolamide 1% ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Azopt 1% Ophthalmic Suspension","otherNames":[]}],"arms":[{"label":"Perrigo active","type":"EXPERIMENTAL"},{"label":"Reference active","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.","primaryOutcome":{"measure":"Mean Change in Intra-ocular Pressure","timeFrame":"6 weeks","effectByArm":[{"arm":"Perrigo Active","deltaMin":-4.25,"sd":2.713},{"arm":"Reference Active","deltaMin":-3.8,"sd":2.719}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":249},"commonTop":["Dysgeusia","vision blurred"]}}